What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?

Autoimmun Rev. 2020 Nov;19(11):102666. doi: 10.1016/j.autrev.2020.102666. Epub 2020 Sep 14.

¹ Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy; Biomolecular Medicine Ph.D. Programme - cycle XXXV, University of Verona, Italy.
² Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy.
³ Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
⁴ Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy; Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Electronic address: elisa.gremese@unicatt.it.

No abstract available

Keywords: Anti-MDA5; COVID-19; Cytokines; Dermatomyositis; Inflammation; Interstitial lung disease.

Publication types